Skip to main content

Table 1 Differences in study parameters between patients with GEP-NET and control group

From: Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?

Parameters GEP-NET patients
n. 109
Control group
n. 109
*p-value
Demographic characteristics
 Gender (Males) 53 (48.6%) 53 (48.6%) χ2 = 0.02, p = 0.892
 Age (years) 57.1 ± 16.0 56.2 ± 12.9 0.370
Clinical characteristics
 Smoking (No) 72 (66.1%) 42 (38.5%) χ2 = 16.54, p < 0.001
 Physical activity (No) 60 (55.0%) 55 (50.5%) χ2 = 0.29, p = 0.587
Anthropometric measurement
 BMI (kg/m2) 27.6 ± 5.3 28.2 ± 4.1 0.364
 Normal weight (n, %) 38 (34.9%) 27 (24.8%) χ2 = 2.19, p = 0.099
 Overweight (n, %) 36 (33.0%) 53 (48.6%) χ2 = 4.86, p = 0.028
 Grade I obesity (n, %) 29 (26.6%) 22 (20.2%) χ2 = 0.92, p = 0.337
 Grade II obesity (n, %) 5 (4.6%) 6 (5.5%) χ2 = 0.01, p = 1.000
 Grade III obesity (n, %) 1 (0.9%) 1 (0.9%) χ2 = 0.51, p = 0.478
 WC Males (cm) 97.4 ± 13.5 92.9 ± 10.3 0.049
 WC Females (cm) 90.5 ± 15.2 84.1 ± 9.8 0.008
Blood pressure
 SBP (mmHg) 125.2 ± 12.0 120.5 ± 12.4 0.007
 DBP (mmHg) 76.7 ± 7.7 75.5 ± 7.9 0.209
Metabolic profile
 Glycemia levels (mg/dL) 108.1 ± 15.5 92.4 ± 14.6 < 0.001
 Total cholesterol (mg/dL) 190.9 ± 41.8 159.0 ± 30.9 < 0.001
Triglycerides (mg/dL) 127.1 ± 51.6 109.7 ± 28.8 0.003
 LDL cholesterol (mg/dL) 118.7 ± 40.0 86.7 ± 31.2 < 0.001
 HDL cholesterol (mg/dL) 46.8 ± 15.3 50.3 ± 8.1 0.034
MetS
 Number parameter 2.1 ± 1.5 1.0 ± 1.1 < 0.001
 Mets presence 40 (36.7%) 15 (13.8%) χ2 = 14.00, p= 0.001
  1. GEP-NET: Gastroenteropancreatic tumors; BMI: body mass index; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; MetS: metabolic syndrome
  2. *A p-value in bold type denotes a significant difference (p < 0.05)